Status:

COMPLETED

Sprinter Legend Balloon Catheter

Lead Sponsor:

Medtronic Vascular

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Open label, single-arm trial to study the safety and effectiveness of the Sprinter Legend 1.25 mm angioplasty balloon.

Detailed Description

The study examines acute outcomes when the Sprinter Legend 1.25mm balloon catheter is used for enlarging coronary luminal diameters during PCI procedures.

Eligibility Criteria

Inclusion

  • Patient is greater than18 years of age and able to give informed consent.
  • Patient with stenotic lesions in coronary arteries or bypass graft stenosis that are suitable for percutaneous coronary intervention (PCI).
  • The patient has single or multiple vessel coronary artery disease and clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, and/or a positive functional study.
  • Female patients of childbearing potential must have a negative pregnancy test within seven (7) days before the procedure.
  • Patient or patient's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective investigational site.
  • Patients with symptomatic ischemic heart disease due to stenotic lesions in coronary arteries or bypass graft stenosis that are amenable to percutaneous treatment.

Exclusion

  • A known hypersensitivity or contraindication to aspirin, heparin, or bivalirudin, anti-platelet medications, or sensitivity to contrast media, which cannot be adequately pre-medicated.
  • A serum creatinine level \> 2.0 mg/dl within seven days prior to index procedure.
  • Evidence of an acute myocardial infarction within 72 hours of the intended index procedure (defined as: Q wave myocardial infarction or non-Q wave myocardial infarction having creatine kinase myocardial-band isoenzyme (CK-MB) or troponin elevated above the Institution's upper limit of normal).
  • During the index procedure, the target lesion requires additional treatment with a cutting balloon, any artherectomy, any laser, thrombectomy, etc.
  • History of stroke or transient ischemic attack (TIA) within the prior 6 months.
  • Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.
  • History of bleeding diathesis or coagulopathy or will refuse blood transfusions.

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

51 Patients enrolled

Trial Details

Trial ID

NCT00961311

Start Date

August 1 2009

End Date

January 1 2010

Last Update

October 26 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Scripps Green Hospital

La Jolla, California, United States, 92037